Cargando…
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of ca...
Autores principales: | Primrose, J N, Bleiberg, H, Daniel, F, Belle, S Van, Mansi, J L, Seymour, M, Johnson, P W, Neoptolemos, J P, Baillet, M, Barker, K, Berrington, A, Brown, P D, Millar, A W, Lynch, K P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362442/ https://www.ncbi.nlm.nih.gov/pubmed/10027321 http://dx.doi.org/10.1038/sj.bjc.6690079 |
Ejemplares similares
-
A phase II trial of marimastat in advanced pancreatic cancer
por: Evans, J D, et al.
Publicado: (2001) -
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
por: Bramhall, S R, et al.
Publicado: (2002) -
Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA
por: Watson, S A, et al.
Publicado: (1999) -
Carcinoembryonic Antigen and Smoking
por: Clarke, Cyril, et al.
Publicado: (1980) -
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
por: Jones, P H, et al.
Publicado: (2004)